JP2019519482A - 自己免疫系の活性化におけるz−ブチリデンフタリドの使用 - Google Patents
自己免疫系の活性化におけるz−ブチリデンフタリドの使用 Download PDFInfo
- Publication number
- JP2019519482A JP2019519482A JP2018556981A JP2018556981A JP2019519482A JP 2019519482 A JP2019519482 A JP 2019519482A JP 2018556981 A JP2018556981 A JP 2018556981A JP 2018556981 A JP2018556981 A JP 2018556981A JP 2019519482 A JP2019519482 A JP 2019519482A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- injection
- medicament
- mononuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 title claims abstract description 52
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 title claims abstract description 52
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 230000001363 autoimmune Effects 0.000 title claims description 23
- 230000004913 activation Effects 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 230000003213 activating effect Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 71
- 210000005087 mononuclear cell Anatomy 0.000 claims description 69
- 239000003814 drug Substances 0.000 claims description 60
- 210000002865 immune cell Anatomy 0.000 claims description 39
- 238000002347 injection Methods 0.000 claims description 31
- 239000007924 injection Substances 0.000 claims description 31
- 230000037396 body weight Effects 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 16
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000002054 transplantation Methods 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 238000010253 intravenous injection Methods 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 239000007928 intraperitoneal injection Substances 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000003651 basophil Anatomy 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 210000001539 phagocyte Anatomy 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 230000002594 corticospinal effect Effects 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 210000005007 innate immune system Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000012431 wafers Nutrition 0.000 description 46
- 239000003795 chemical substances by application Substances 0.000 description 35
- 241000700159 Rattus Species 0.000 description 23
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 238000002659 cell therapy Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007975 buffered saline Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000012595 freezing medium Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- -1 auxiliaries Substances 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003752 hydrotrope Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LFPLRGMCQXEYDO-UHFFFAOYSA-N 4-[1-(4-carboxyphenoxy)propoxy]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1OC(CC)OC1=CC=C(C(O)=O)C=C1 LFPLRGMCQXEYDO-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
(1)Z−BPを含む第1の部分;および
(2)単核細胞を含む第2の部分、
を含み、前記第1の部分および第2の部分は対象に同時にまたは別々に投与される、自己免疫系を活性化するためのキットを提供することである。
上記のように、PDL−1は、癌細胞の表面上に発現する免疫チェックポイント抗原であり、免疫細胞に結合し、免疫細胞を誘発して免疫応答の抑制を開始することができ、したがって、自己および外来性免疫細胞の両方が活性化されることを不可能にし、さらには免疫細胞を死滅させることも可能である。
(2−1)単核細胞の調製
心臓穿刺により実験用ラットから10mlの全血を採取し、採血管(BD Vacutainerから購入、番号:367988)に入れ、500−1800gで15分間遠心分離した。次いで、上清を除去し、単核細胞層を別の遠心チューブに入れた。その後、以下の実験のために、単核細胞(すなわち、末梢血単核球、PBMC)をPBSで1×106細胞/100μlの濃度に希釈した。
24匹のF344ラットに、1.5〜2%のイソフルランガスを用いた吸入麻酔を施した後、各ラットの脳に2mmの穴を穿孔した。その後、RG2細胞液(1×105細胞/10μl/ラット)をラットの線条体に注射して縫合し、その場で悪性脳膠芽細胞腫動物モデルを樹立した。3日後、以前の穿孔を中心とし半径10mmの穴を穿孔した後、ラットを無作為に4群(各群6匹)に分け、以下のように処理して次の実験を行った。
(1)「空のウェハー剤」群:活性成分を含まないウェハー剤(EVERFRONT BIOTECH社製)を各ラットの脳に入れた。
(2)「空のウェハー剤+PBMC」群:各ラットの脳に活性成分を含まないウェハー剤を入れ、(2−1)で得られた1×106個のPBMCを尾静脈内注射により各ラットに投与した。
(3)「Cerebracaウェハー剤」群:各ラットの脳に、Z−BP(7.5mgZ−BP/ウェハー剤;EVERFRONT BIOTEC社製)を入れたウェハー剤を入れた。
(4)「Cerebracaウェハー剤+PBMC」群:各ラットの脳にZ−BP(7.5mgZ−BP/ウェハー剤)を入れたウェハー剤を入れ、(2−1)で得られた1×106個のPBMCを尾静脈注射により投与した。
各群のラットの生存状況を毎日観察し、記録した。結果を図2および表1に示す。
[表1]
(2−3)のラットが死亡した後、脳を採取して病理組織切片を調製した。次いで、病理組織切片の腫瘍部位においてCD4、CD8、CD11b、およびCCL20抗体(Genetex社から購入)を用いて免疫組織染色(IHC)を行い、顕微鏡で観察した。結果を図3に示す。
Claims (18)
- 医薬の製造におけるZ−ブチリデンフタリド(Z−BP)の使用であって、前記医薬が自己免疫系を活性化するために使用される、使用。
- 前記医薬が単核細胞と組み合わせて使用される、請求項1に記載の使用。
- 前記単核細胞が、自己単核細胞、外来性単核細胞、およびそれらの組み合わせからなる群より選択される、請求項2に記載の使用。
- 前記単核細胞が、リンパ細胞、骨髄細胞、食細胞および抗原提示細胞の少なくとも1つである、請求項2に記載の使用。
- 前記単核細胞が、T細胞、B細胞、NK細胞、肥満細胞、好塩基球顆粒球、好酸球顆粒球、好中球、マクロファージ、および樹状細胞の少なくとも1つである、請求項2に記載の使用。
- 前記医薬が、経口投与、経皮投与、経鼻投与、皮下注射、静脈内注射、筋肉内注射、腹腔内注射、皮下移植、間質移植、または前記投与形態の2つ以上によって投与される、請求項1に記載の使用。
- 前記医薬が、ウェハー剤の形態である、請求項6に記載の使用。
- 前記医薬が、癌細胞の免疫チェックポイント抗原の発現を阻害すること、免疫系を活性化することができるケモカインを分泌するように癌細胞を促進すること、免疫細胞の量を増加させること、および免疫細胞の腫瘍部位への進入を促進することのいずれか1つに使用される、請求項1〜7のいずれか1項に記載の使用。
- 前記癌細胞が、悪性脳腫瘍細胞、神経膠芽腫細胞、膵臓癌細胞、肺癌細胞、およびメラノサイトーマ細胞のうちの少なくとも1つである、請求項8に記載の使用。
- 前記医薬が1日あたり約30mg/kg体重〜約2,000mg/kg体重の範囲の量で投与される、請求項1〜7のいずれか1項に記載の使用。
- 前記医薬が1日あたり約30mg/kg体重〜約2,000mg/kg体重の範囲の量で投与される、請求項9に記載の使用。
- (1)Z−BPを含む第1の部分;および
(2)単核細胞を含む第2の部分、
を含む自己免疫系を活性化するためのキットであって、前記第1の部分および第2の部分は、対象に同時にまたは別々に投与される、キット。 - 前記単核細胞が、自己単核細胞、外来性単核細胞、およびそれらの組み合わせからなる群より選択される、請求項12に記載のキット。
- 前記単核細胞が、リンパ球、骨髄細胞、食細胞および抗原提示細胞の少なくとも1つである、請求項12に記載のキット。
- 前記単核細胞が、T細胞、B細胞、NK細胞、肥満細胞、好塩基球顆粒球、好酸球顆粒球、好中球、マクロファージ、および樹状細胞の少なくとも1つである、請求項12に記載のキット。
- 前記第1の部分が、経口投与、経皮投与、経鼻投与、皮下注射、静脈内注射、筋肉内注射、腹腔内注射、皮下移植、および/または間質移植に適した第1の形態として提供され、前記第2の部分は、皮質脊髄路注射、髄腔内注射、脳内注射、静脈内注射、腹腔内注射および/または皮下注射に適した第2の形態として提供される、請求項12〜15のいずれか1項に記載のキット。
- 前記第1の部分がウェハー剤として提供される、請求項16に記載のキット。
- 溶液を含む第3の部分をさらに含み、使用前に、前記溶液を前記第2の部分と混合して注射用溶液を提供する、請求項17に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662340246P | 2016-05-23 | 2016-05-23 | |
US62/340,246 | 2016-05-23 | ||
PCT/CN2017/084455 WO2017202227A1 (zh) | 2016-05-23 | 2017-05-16 | Z-亚丁基苯酞于活化自体免疫系统的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019519482A true JP2019519482A (ja) | 2019-07-11 |
JP6824287B2 JP6824287B2 (ja) | 2021-02-03 |
Family
ID=60329303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556981A Active JP6824287B2 (ja) | 2016-05-23 | 2017-05-16 | 自己免疫系の活性化におけるz−ブチリデンフタリドの使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10688128B2 (ja) |
EP (1) | EP3466422B1 (ja) |
JP (1) | JP6824287B2 (ja) |
CN (1) | CN109069478B (ja) |
ES (1) | ES2850498T3 (ja) |
TW (1) | TWI640310B (ja) |
WO (1) | WO2017202227A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021143754A1 (zh) * | 2020-01-14 | 2021-07-22 | 长弘生物科技股份有限公司 | 用于癌症治疗的组合及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08510118A (ja) * | 1993-05-18 | 1996-10-29 | イ・デ・エム・イミュノ−デジネ・モレキュル | 新規なマクロファージ、その製造方法、及び医薬組成物の活性物質としてのその用途 |
JP2007082422A (ja) * | 2005-09-20 | 2007-04-05 | Oncorex Inc | 低酸素条件下において遊走能を有する樹状細胞、およびその利用 |
CN1943606A (zh) * | 2005-10-08 | 2007-04-11 | 财团法人佛教慈济综合医院 | 用于治疗癌症的当归萃取物 |
JP2012144512A (ja) * | 2011-01-07 | 2012-08-02 | China Medical Univ | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 |
JP2015229675A (ja) * | 2014-06-04 | 2015-12-21 | 中國醫藥大學 | 膵臓癌を治療するための医薬製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10120505A1 (de) * | 2001-04-26 | 2002-11-07 | Rudolf Wank | Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen |
JP4781771B2 (ja) * | 2004-10-08 | 2011-09-28 | 財團法人佛教慈濟総合醫院 | ガン治療用の当帰抽出物 |
CN101184484B (zh) * | 2005-05-24 | 2011-10-05 | 帝斯曼知识产权资产管理有限公司 | 用于治疗炎性失调的藁本内酯衍生物 |
TWI331033B (en) * | 2007-04-26 | 2010-10-01 | Yangsen Biotechnology Co Ltd | Composition for inhibiting no and/or prostaglandin e2 synthesis and uses thereof |
DK2343051T3 (da) * | 2010-01-05 | 2014-10-27 | Nat Univ Dong Hwa | Anti-cancer formulering |
US20140065096A1 (en) * | 2012-09-05 | 2014-03-06 | Regen BioPharma, Inc. | Cancer therapy by ex vivo activated autologous immune cells |
US20170216419A1 (en) * | 2014-07-22 | 2017-08-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods for cancer immunotherapy |
-
2017
- 2017-05-16 CN CN201780028428.9A patent/CN109069478B/zh active Active
- 2017-05-16 TW TW106116111A patent/TWI640310B/zh active
- 2017-05-16 WO PCT/CN2017/084455 patent/WO2017202227A1/zh active Search and Examination
- 2017-05-16 EP EP17802073.1A patent/EP3466422B1/en active Active
- 2017-05-16 ES ES17802073T patent/ES2850498T3/es active Active
- 2017-05-16 US US15/596,858 patent/US10688128B2/en active Active
- 2017-05-16 JP JP2018556981A patent/JP6824287B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08510118A (ja) * | 1993-05-18 | 1996-10-29 | イ・デ・エム・イミュノ−デジネ・モレキュル | 新規なマクロファージ、その製造方法、及び医薬組成物の活性物質としてのその用途 |
JP2007082422A (ja) * | 2005-09-20 | 2007-04-05 | Oncorex Inc | 低酸素条件下において遊走能を有する樹状細胞、およびその利用 |
CN1943606A (zh) * | 2005-10-08 | 2007-04-11 | 财团法人佛教慈济综合医院 | 用于治疗癌症的当归萃取物 |
JP2012144512A (ja) * | 2011-01-07 | 2012-08-02 | China Medical Univ | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 |
JP2015229675A (ja) * | 2014-06-04 | 2015-12-21 | 中國醫藥大學 | 膵臓癌を治療するための医薬製剤 |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF NEUROCHEMISTRY, vol. 99, JPN6019039299, 2006, pages 1251 - 1262, ISSN: 0004410879 * |
MOLECULES, vol. Vol.21, 549, JPN6019039300, 26 April 2016 (2016-04-26), pages 1 - 11, ISSN: 0004410880 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017202227A1 (zh) | 2017-11-30 |
EP3466422A4 (en) | 2020-03-11 |
JP6824287B2 (ja) | 2021-02-03 |
CN109069478B (zh) | 2021-07-06 |
US10688128B2 (en) | 2020-06-23 |
ES2850498T3 (es) | 2021-08-30 |
CN109069478A (zh) | 2018-12-21 |
TWI640310B (zh) | 2018-11-11 |
EP3466422B1 (en) | 2020-11-18 |
TW201740938A (zh) | 2017-12-01 |
US20170333478A1 (en) | 2017-11-23 |
EP3466422A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220265824A1 (en) | Hematologic cancer treatments | |
RU2708332C2 (ru) | Лечение лимфом | |
US20210283063A1 (en) | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | |
JP2016516080A (ja) | 骨髄性白血病の処置方法 | |
US20160361358A1 (en) | Pharmaceutical containing dendritic cells, and method for producing same | |
CN105358678A (zh) | 治疗和/或预防1型糖尿病的方法和组合物 | |
JP6824287B2 (ja) | 自己免疫系の活性化におけるz−ブチリデンフタリドの使用 | |
WO2020201444A1 (en) | Repurposing small molecules for senescence-related diseases and disorders | |
US20160113936A1 (en) | Methods for modulating monocyte function | |
WO2020092650A1 (en) | Compositions and methods for modulating t cell exhaustion | |
JP6489517B2 (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
US20230087078A1 (en) | Compositions and methods for the treatment of pancreatic cancer | |
CN110753551A (zh) | 使用nk-92细胞治疗梅克尔细胞癌(mcc)的方法 | |
TWI327473B (en) | Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin | |
WO2017106584A1 (en) | Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor | |
WO2015046574A1 (ja) | 虚血後の再灌流に起因する出血を予防するための薬剤 | |
CN110494137B (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 | |
CN102614180A (zh) | 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用 | |
WO2008111918A2 (en) | Combination containing plant extracts and use thereof for the treatment of various types of cancer | |
CN111035758A (zh) | 药物组合物及其应用、无菌容器和试剂盒 | |
CN114617969A (zh) | 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用 | |
JP2005139092A (ja) | 腎機能障害予防・治療用細胞製剤とその製造方法、腎機能障害の予防・治療方法 | |
Yamamoto | Infeluences of adrenalin, cortisone and ACTH on eosinophils in bone marrow tissue culture (With some suggestions for examining the anterior pituitary function) | |
Chan et al. | Cranioselectivity of sumatriptan revisited |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200512 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201109 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201109 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201118 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6824287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |